Skip to main content

Table 1 Relationship between clinicopathological factors and 95GC results

From: Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer

Factors

95GC-L

(N = 47)

N (%)

95GC-H

(N = 28)

N (%)

Total

(N = 75)

N (%)

p-value

Age

≤50 years

14 (29.8)

11 (39.3)

25 (33.3)

p = 0.453

> 50 years

33 (70.2)

17 (60.7)

50 (66.7)

 

T stage

T1

30 (63.8)

16 (57.1)

46 (61.3)

p = 0.628

T2

17 (36.2)

12 (42.9)

29 (38.7)

 

Histology

Ductal

43 (91.5)

28 (100.0)

71 (94.7)

p = 0.384

Lobular

1 (2.1)

0 (0.0)

1 (1.3)

 

Other

3 (6.4)

0 (0.0)

3 (4.0)

 

Histologic grade

1

8 (17.0)

2 (7.1)

10 (13.3)

p < 0.001

2

33 (70.2)

10 (35.7)

43 (57.3)

 

3

6 (12.8)

15 (53.6)

21 (28.0)

 

NA

0 (0.0)

1 (3.6)

1 (1.3)

 

PR

Negative

9 (19.1)

7 (25.0)

16 (21.3)

p = 0.572

Positive

38 (80.9)

21 (75.0)

59 (78.7)

 

HER2

Negative

46 (97.9)

26 (92.9)

72 (96.0)

p = 0.552

Positive

1 (2.1)

2 (7.1)

3 (4.0)

 

Ki-67

< 20%

37 (78.7)

16 (57.1)

53 (70.7)

p = 0.024

≥20%

4 (8.5)

8 (28.6)

12 (16.0)

 

NA

6 (12.8)

4 (14.3)

10 (13.3)

 

PAM50

Luminal A

22 (46.8)

0 (0.0)

22 (29.3)

p < 0.001

Luminal B

7 (14.9)

16 (57.1)

23 (30.7)

 

HER2

1 (2.1)

4 (14.3)

5 (6.7)

 

Basal

2 (4.3)

8 (28.6)

10 (13.3)

 

Normal

15 (31.9)

0 (0.0)

15 (20.0)

 
  1. NA not available